Research could help minimize unnecessary exposure to drugs with potential side effects

February 25, 2014 by Elaine Smith, University of Toronto Mississauga

Patients with advanced non-small cell lung cancer (NSCLC) often suffer the challenging side effects of drug regimens that may not have any impact, says Jayson Parker, PhD, a lecturer at U of T Mississauga. Meanwhile pharmaceutical companies are experiencing rising costs to bring new drugs to market for patients.

Now, a new study by Parker and his colleagues at the Leslie Dan Faculty of Pharmacy and Johns Hopkins University, published in the February issue of the Journal of Thoracic Oncology, illustrates how the pain and the wasted time and money may be more easily avoided.

"When you take medication, you want it to be responsive because you may have to endure the negative side effects," says Parker, the lead author. "We also want to reduce the number of red herrings that are pursued by ."

Personalized medicine tailors medicines to patients based on their unique metabolism and genetics (biomarkers) that may identify them as responders to a . In the study, Parker and his colleagues have determined that drugs administered to NSCLC patients during clinical trials during the past 14 years have a meagre success rate of 11 per cent overall, while the drugs that target cells with a biomarker have a cumulative success rate of 62 per cent. The study encompasses drugs submitted to the U.S. Food and Drug Administration for approval.

In addition, Parker and his fellow researcher have found that the success rate for complex drugs that targeted a receptor – a protein sitting on the surface of a cell – had a 31 per cent cumulative success rate, compared to 11 per cent for simpler, small-molecule drugs that didn't focus on a target.

"This research could help minimize unnecessary exposure to drugs with potential side effects, such as chemotherapy drugs, for people with advanced non-small cell lung cancer," says Parker. Being strategic about drug development is "also a way of making research and development more cost effective by reducing the number of dead ends," he said.

"There is an estimated cost of $1.5-2 billion dollars to bring a new drug to market, because we also have to pay for the failures. This could save drug developers about $400 million per drug for NSCLC."

Lung cancer is the second most commonly diagnosed cancer in Canada, other than non-melanoma skin cancers, according the Canadian Cancer Society. In 2013, it was estimated that 25,000 Canadians would be diagnosed with lung cancer and 20,200 Canadians would die of the disease, accounting for 27 per cent of all Canadian cancer deaths. The current five-year survival rate for is just 17 per cent.

Explore further: Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC

Related Stories

Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC

February 14, 2014
Over the past decade, a great clinical focus has been directed at developing new and innovative therapies for advanced non-small cell lung cancer (NSCLC). An analysis of clinical trials evaluating these therapies demonstrates ...

Biological markers increase clinical trial success rate of new breast cancer drugs

October 1, 2012
Using biological markers—genetic characteristics that are associated with some patients with breast cancer—can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research ...

Blocking 'lock and key' site of lung cancer proteins could lead to new treatments

November 12, 2013
A Cancer Research UK study reveals that stopping two essential lung cancer proteins from joining together at their 'lock and key' site could lead to new treatments for the disease. The research is published in the journal ...

New therapy is tolerable in lung cancer

May 31, 2013
A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's ...

FDA approves new drug for advanced lung cancer

July 12, 2013
(HealthDay)—A new drug to treat advanced lung cancer has been approved by the U.S. Food and Drug Administration.

Why combination drug treatment ineffective in cancer clinical trials

December 5, 2013
Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.